|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 227 Massachusetts Avenue, NE, Suite 1 |
Address2 | |
City | Washington |
State | DC |
Zip Code | 20002 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 51478-75
|
||||||||
|
6. House ID# 349270003
|
TYPE OF REPORT | 8. Year | 2008 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Mr. Brad Holsclaw, Partner |
Date | 04/21/2008 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Issues related to follow-on biologics, drug safety, importation/reimportation of prescription drugs, drug advertising, and the Citizen's Petition process, including such provisions in S1082 "The Food and Drug Administration Revitalization Act" and HR3580. "The Food and Drug ADministration Amendment Act of 2007", and HR3610 "Fodd and Drug Safety Act of 2007"; HR1038 "Access to Life-Saving Medicine Act" and S1695 "Biologics Price Competition and Innovation Act of 2007" All provisions.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brad |
Holsclaw |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
sanofi-aventis U.S. inc. is an international company with headquarters in Paris, France.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Issues and provisions related to the closure of the Medicare Part D donut hole and other improvements for beneficiaries of the Medicare program, and the Medicaid drug rebate, including such provisions in HR3162 "The Children's Health and Medicare Protection Act of 2007 and S1607, "The Children's Health Insurance Program Reauthorization Act of 2007." Coding and reimbursement of coverage issues for Medicare Part B products and Medicare Part D services, preventative health screenings and
assessments, and obesity drugs; issues relatd to DVT prevention and awareness, including draft legislation "Deep Vein Thrombosis Prevention Act of 2007"; issues related to osteoporosis prevention, awareness, and screening.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brad |
Holsclaw |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
sanofi-aventis U.S. inc. is an international company with headquarters in Paris, France.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Issues related to importation/reimportation of prescription drugs and the Labor HHS-Education Appropriations Act.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brad |
Holsclaw |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
sanofi-aventis U.S. inc. is an international company with headquarters in Paris, France.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
HR 3610 "Food and Drug Import Safety Act of 2007"; S. 242, HR 380, "Pharmaceutical Market Access and Drug Safety Act of 2007", HR 2638, "Department of Homeland Security Appropriations Act, 2008"; H. AMDY 734 to HR 3161 and S1859 "agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Act, 2008" (provisions related to imporation of prescription pharmaceuticals, safety inspections of such products, and the adequacy to protect the American public
from counterfeit, adultered, and sub-potent products. HR2606 and S1376 "340B Program Improvement and Integrity Act of 2007"; HR380 "Pharmaceutical Market Access and Drug Safety Act of 2007" (provisions related to proposed changes to the 340B federal drug pricing program).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brad |
Holsclaw |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
sanofi-aventis U.S. inc. is an international company with headquarters in Paris, France.
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |